Foscarnet

證據等級: L5

預測適應症: 4 個

Foscarnet: From Antiviral Therapy to Autosomal Dominant Familial Hematuria–Retinal Arteriolar Tortuosity–Contractures Syndrome

One-Sentence Summary

Foscarnet (DrugBank DB00529) is known — per the evidence pack’s own rationale text — as a pyrophosphate analog antiviral active against CMV, HSV, and VZV; no formal original-indication or Taiwan license record is on file for this candidate. The TxGNN model predicts a possible link to Autosomal Dominant Familial Hematuria–Retinal Arteriolar Tortuosity–Contractures Syndrome with a 99.56% prediction score, but this is supported by zero clinical trials and zero publications — a pure model signal with no corroborating evidence.

Quick Overview

Item	Content
Original Indication	Not on file — no TFDA license record and `original_indications` is empty. Known antiviral use (CMV, HSV, VZV) referenced only in the rationale text, not a licensed indication
Predicted New Indication	Autosomal dominant familial hematuria–retinal arteriolar tortuosity–contractures syndrome
TxGNN Prediction Score	99.56% (rank 10,857)
Evidence Level	L5
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for foscarnet is not available in this evidence pack — it is flagged as a High-severity data gap (DG002). Based on the rationale text carried alongside the prediction, foscarnet is a pyrophosphate analog that selectively inhibits viral DNA polymerase and reverse transcriptase, giving it activity against CMV, HSV, and VZV. This is an antiviral mechanism, not one associated with any genetic connective-tissue or vascular disorder.

The predicted new indication is a rare, COL4A1-related hereditary vascular collagenopathy. The evidence pack’s own repurposing rationale explicitly states there is no known mechanistic link between foscarnet’s antiviral activity and COL4A1-related vascular pathology. The 99.56% score reflects a pure knowledge-graph prediction signal and is not corroborated by any clinical trial or literature evidence — it should be treated as a hypothesis-generation output only, not a validated pharmacological rationale.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Foscarnet currently holds no license record on file (market_status: 未上市 / Not Marketed; total_licenses: 0). No marketing-authorization table is available.

Safety Considerations

Please refer to the package insert for safety information. Note: TFDA label warnings/contraindications are a Blocking data gap (DG001) — this must be resolved before any S1 safety screening can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication has zero clinical trial or literature support and is driven purely by the TxGNN score (L5); the evidence pack’s own rationale confirms no known mechanistic link exists. Combined with the absence of a Taiwan market license and a Blocking gap in MOA/label data, the candidate does not clear the bar to advance past S0.

To proceed, the following is needed:

TFDA label warnings/contraindications (DG001, Blocking — required before S1 safety screening)
Confirmed mechanism of action (DG002, High — required for mechanistic plausibility review)
Original approved indication(s) for foscarnet, to establish a repurposing baseline
Independent literature or clinical evidence directly linking foscarnet to this indication, since the TxGNN score alone is insufficient to support advancement

Note: three additional TxGNN-predicted indications for foscarnet were also reviewed in this evidence pack — rheumatoid arthritis, diabetic nephropathy, and brain small vessel disease 1 with or without ocular anomalies. All three received the same Hold recommendation; retrieved trials/literature for each were keyword-mismatched (e.g., an unrelated brolucizumab/AMD trial, or CMV-treatment case reports mentioning foscarnet only incidentally) rather than substantive support for the stated indication.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.